X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs CIPLA - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD CIPLA MERCK LTD/
CIPLA
 
P/E (TTM) x 46.4 33.7 137.6% View Chart
P/BV x 6.8 2.9 230.3% View Chart
Dividend Yield % 0.5 0.6 87.0%  

Financials

 MERCK LTD   CIPLA
EQUITY SHARE DATA
    MERCK LTD
Dec-17
CIPLA
Mar-18
MERCK LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,358663 204.8%   
Low Rs933479 194.8%   
Sales per share (Unadj.) Rs665.0189.0 351.8%  
Earnings per share (Unadj.) Rs56.617.6 321.5%  
Cash flow per share (Unadj.) Rs72.534.0 213.0%  
Dividends per share (Unadj.) Rs15.003.00 500.0%  
Dividend yield (eoy) %1.30.5 249.3%  
Book value per share (Unadj.) Rs441.7176.7 249.9%  
Shares outstanding (eoy) m16.60805.12 2.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.73.0 57.0%   
Avg P/E ratio x20.232.5 62.4%  
P/CF ratio (eoy) x15.816.8 94.2%  
Price / Book Value ratio x2.63.2 80.2%  
Dividend payout %26.517.1 155.5%   
Avg Mkt Cap Rs m19,011459,724 4.1%   
No. of employees `0001.523.6 6.5%   
Total wages/salary Rs m1,69626,901 6.3%   
Avg. sales/employee Rs Th7,150.06,446.1 110.9%   
Avg. wages/employee Rs Th1,098.71,139.4 96.4%   
Avg. net profit/employee Rs Th608.2600.0 101.4%   
INCOME DATA
Net Sales Rs m11,040152,193 7.3%  
Other income Rs m2403,577 6.7%   
Total revenues Rs m11,279155,769 7.2%   
Gross profit Rs m1,37628,264 4.9%  
Depreciation Rs m26413,228 2.0%   
Interest Rs m01,142 0.0%   
Profit before tax Rs m1,35217,470 7.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m170-775 -21.9%   
Tax Rs m5832,501 23.3%   
Profit after tax Rs m93914,166 6.6%  
Gross profit margin %12.518.6 67.1%  
Effective tax rate %43.114.3 301.1%   
Net profit margin %8.59.3 91.4%  
BALANCE SHEET DATA
Current assets Rs m7,523108,141 7.0%   
Current liabilities Rs m2,25338,322 5.9%   
Net working cap to sales %47.745.9 104.1%  
Current ratio x3.32.8 118.4%  
Inventory Days Days5297 53.8%  
Debtors Days Days4174 54.5%  
Net fixed assets Rs m1,240109,411 1.1%   
Share capital Rs m1661,610 10.3%   
"Free" reserves Rs m7,167140,682 5.1%   
Net worth Rs m7,333142,292 5.2%   
Long term debt Rs m036,621 0.0%   
Total assets Rs m9,912228,606 4.3%  
Interest coverage xNM16.3-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.10.7 167.3%   
Return on assets %9.56.7 141.5%  
Return on equity %12.810.0 128.6%  
Return on capital %20.810.0 208.5%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,01551,691 2.0%   
Fx outflow Rs m3,04321,033 14.5%   
Net fx Rs m-2,02830,658 -6.6%   
CASH FLOW
From Operations Rs m53714,628 3.7%  
From Investments Rs m-476-8,540 5.6%  
From Financial Activity Rs m-220-3,855 5.7%  
Net Cashflow Rs m-1602,431 -6.6%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 51.8 20.8 249.0%  
Indian inst/Mut Fund % 18.2 12.2 149.2%  
FIIs % 1.0 23.7 4.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 29.1 26.2 111.1%  
Shareholders   28,591 161,166 17.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   UNICHEM LAB  PANACEA BIOTECH  CADILA HEALTHCARE  TORRENT PHARMA  PLETHICO PHARMA  

Compare MERCK LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Nov 14, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD 8-QTR ANALYSIS

COMPARE MERCK LTD WITH

MARKET STATS